Microarray analysis points to LMNB1 and JUN as potential target genes for predicting metastasis promotion by

Jiafei Liu1,2,3, Hongjie Yang1,2,3, Peng Li1,2,3

  • 1Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, People's Republic of China.

Scientific Reports
|October 10, 2024
PubMed

Insights

Etoposide chemotherapy may unexpectedly enhance colorectal cancer metastasis by altering gene expression. Researchers identified LMNB1 and JUN as potential biomarkers for predicting this increased cancer cell motility.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Etoposide is a chemotherapy drug used for metastatic colorectal cancer.
  • This study investigated the unexpected finding that etoposide treatment can increase colorectal cancer cell motility.

Purpose of the Study:

  • To explore the molecular mechanisms by which etoposide promotes colorectal cancer metastasis.
  • To identify potential biomarkers for predicting etoposide-induced cancer cell motility.

Main Methods:

  • Microarray analysis of mRNA expression in four colorectal cancer cell lines after etoposide treatment.
  • Differential gene expression analysis, Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and KEGG Pathway analysis.
  • Interaction analysis of differentially expressed genes using the STRING database.

Main Results:

  • Etoposide treatment significantly altered gene expression, downregulating cell cycle, metabolism, and senescence pathways.
  • Necroptosis and oncogene pathways were significantly upregulated post-etoposide treatment.
  • Eight interacting genes (FAS, HMMR, JUN, LMNB1, MLL3, PLK2, STAG1, TBL1X) were identified among the top differentially expressed genes.

Conclusions:

  • The study suggests that etoposide can promote colorectal cancer metastasis.
  • LMNB1 and JUN gene expression are proposed as potential predictive biomarkers for colorectal cancer metastasis.
  • Findings offer clinical guidance for chemotherapy and direct future research into metastasis mechanisms.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.4K